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Summary 
The pathogenesis of obesity-related vascular disorders has not been fully elucidated. The fundamental role of inflammation in aging process is 
now widely recognized, particularly for atherosclerotic disease which begins before birth. The number of obese individuals worldwide has reached two 
billion, leading to an explosion of obesity-related vascular disorders associated with increased morbidity and mortality. Obesity, as a chronic low grade 
inflammatory process, is important risk factor for metabolic and cardiovascular disease. Despite a well-known genetic component, this risk appears to 
originate from several abnormalities in adipose tissue function associated with a chronic inflammatory state. In particular, obesity as the most common 
nutritional disorder in industrialized countries, is closely related to impaired endothelial function, a well-known marker of preatherosclerotic disease. 
These conditions disrupt vascular homeostasis by causing an imbalance between the nitric oxide pathway and the endothelin-1 system, with impaired 
insulin-stimulated endothelium-dependent vasodilation. Having in mind the growing population of overweight and obese people worldwide, along 
with an increasingly aging population, understanding the pathophysiology of obesity on cardiovascular system is essential. The mechanisms linking 
obesity-related vascular disorders and low grade inflammation in aging process are the focus of this paper.  
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Sažetak
Patogeneza vaskularnih poremećaja koji su povezani sa gojaznošću nije u potpunosti razjašnjena. Danas je poznata fundamentalna uloga infla-
macije u procesu starenja, naročito kod aterosklerozne bolesti, koja počinje pre rođenja. Broj gojaznih osoba širom sveta je dostigao cifru dva biliona i 
doveo do “eksplozije” vaskularnih poremećaja koji su povezani sa gojaznošću i povećanim morbiditetom i mortalitetom. Gojaznost, kao hronični nisko-
stepeni inflamacijski proces, je važan faktor rizika za nastanak metaboličkih i kardiovaskularnih bolesti. Pored dobro proučene genetske komponente, 
izgleda da je za ovaj rizik zaslužno i nekoliko poremećaja funkcije masnog tkiva koji se dovode u vezu sa stanjem hronične inflamacije. U tom smislu 
prednjači gojaznost, pošto je kao najčešći poremećaj ishrane u razvijenim zemljama blisko povezana sa endotelnom disfunkcijom, koja predstavlja 
uveliko poznat marker preaterosklerozne bolesti. Takvi uslovi narušavaju vaskularnu homeostazu, dovodeći do dizbalansa između metaboličkog puta 
azot monoksida i sistema endotelina-1, što je praćeno otežanim odvijanjem insulinom podstaknute vazodilatacije. Imajući u vidu globalni zajednički 
porast broja kako osoba sa viškom kilograma i gojaznih osoba, tako i starije populacije, razumevanje patogeneze gojaznosti i njenog uticaja na kar-
diovaskularni sistem je od esencijalnog značaja. Mehanizmi koji čine sponu između vaskularnih poremećaja povezanih sa gojaznošću i niskostepene 
inflamacije u procesu starenja nalaze se u fokusu ovog rada.    
Ključne reči: inflamacija, starenje, vaskularni poremećaji povezani sa gojaznošću, insulinska rezistencija, adipokini  
INTRODUCTION
Discovery consists of seeing what everybody has seen  and thinking what nobody has thought /Albert Szent-Gyorgyi/.
Inflammatory process is a part of the host immune de-
fenses to pathogens and tissue responses to injury. In-
flammatory reactions engage and operate at all levels of 
biological organization, from free radicals to behavior 
(1). Inflammation may be considered a core process of 
human aging because of its involvement in baseline ag-
ing and in the major degenerative diseases of later life, 
atherosclerosis, Alzheimer’s disease and cancer (2). 
Blood levels of C-reactive protein (CRP), interleukin-6 
(IL-6) and other proinflammatory cytokines are risk 
indicators of cardiovascular events and mortality (3). 
Even in the absence of specific pathological lesions, in-
flammatory gene expression increases during aging in 
humans and animal models (1, 3).
The acute phase of inflammation largely involves the 
innate immune responses, whereas subsequent phases 
may include adaptive immune responses of antigen-se-
lected T and B cells, but with continuing mediation 
by various innate immune factors (1). Because tissue 
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damage activates gene responses shared with the acute 
phase, most degenerative diseases of aging involve in-
nate immune responses. Thus, it is very difficult to 
resolve cause and effect in the slow inflammatory pro-
cesses that may be shared across tissues during chron-
ic degenerative diseases of aging (1-3). Besides, foci of 
chronic inflammation also typically stimulate local cell 
proliferation, which in some instances progresses to cel-
lular (proliferative) senescence (1, 4-6).
Obesity is understood as a proinflammatory state with 
chronic activation of acute phase responses (7-9). Blood 
CRP and IL-6 are strongly correlated with the degree 
of obesity across a broad range of the body mass index 
(BMI) (10). White adipose depots contain numerous 
macrophages, which secrete proinflammatory cyto-
kines (11). Visceral fat in particular secretes adipokines 
and IL-6 (12). Adipocytes from diabetics show in-
creased cytokine production, telomere shortening and 
other markers of senescence (13). The increased blood 
inflammatory profile in obesity is linked to insulin re-
sistance (IR), diabetes, cardiovascular disease (CVD) 
and cancer (14).
Table 1. Inflammatory response levels modified according to Finch, 2010 
Biological level ROS oxidation of DNA, lipids and proteins;
glycooxidation (AGE formation)
Cellular level activation of macrophages by endotoxins;
oxidized proteins, lipids and AGE;
autogenous inflammation from replicative cell 
senescence
Systemic level humoral elevation of CRP, IL-6 and cytokines;
redox shift in glutathione;
induction of fever by IL-6 and TNFα;
increased basal metabolic rate;
lethargy and other sickness behaviors
Environmental infectious pathogens that cause systemic in-
flammation and focal lesions;
ambient inflammogens from combustion of 
fossil fuels and tobacco
Abbreviations: ROS-reactive oxygen species; DNA-deoxyribonuc-
leic acid;  AGE- advanced glycation end products; CRP- C reactive 
protein; IL-6 – interleukin 6; TNFα; tumor necrosis factor alpha 
Inflammation-associated cellular-molecular damage 
is recognized as a major feature in aging (3). By-stan-
der damage by reactive oxygen species (ROS) to neigh-
boring cells and molecules is an important source of 
oxidative damage during aging that interacts with the 
endogenous damage from free radicals (1-3). The activa-
tion of macrophages and neutrophils increases secreti-
on of ROS, which can cause oxidative by-stander dama-
ge to deoxyribonucleic acid (DNA) and proteins within 
a cell and neighboring cells and extracellular proteins 
(1). Immune activation in response to specific antigens 
can also have by-stander effects through secretion of 
interferon γ (IFNγ) and other cytokines that influen-
ce the differentiation of neighboring T cells (2). Thus, 
the oxidized molecules from by-stander damage are 
recognized by macrophages-through RAGE receptors 
(receptors for AGE /advanced glycation endproducts/) 
(15, 16). These transmembrane receptors can stimulate 
further inflammatory reactions (1). RAGE has broad 
ligand binding and is a mediator of systemic oxidative 
stress and inflammatory responses (15-18). Addition-
ally, blood glucose concentration is directly linked to 
inflammatory changes in many aspects of aging, by 
driving the formation of AGE, which in turn is directly 
linked to vascular disease (1). Microbial pathogens also 
activate RAGE (19).     
Obesity, as a chronic low grade inflammatory process, 
can damaging effects on many organ systems (20, 21). 
Namely, the number of obese individuals worldwide 
has reached two billion, leading to an explosion of obe-
sity-related health problems associated with increased 
morbidity and mortality (20, 22, 23). Many of the comor-
bid conditions are related to metabolic syndrome (MS), 
characterized by a visceral (abdominal) obesity, dys-
lipidemia, glucose intolerance and high arterial blood 
pressure (24-26). The prevalence of the MS is age-de-
pendent. Advancing age affects all levels of pathogenic 
components of the MS (27-29). Age-related alterations 
contributing to the increased prevalence of the MS in 
elderly subjects is presented in Table 2 (27). Each com-
ponent of MS is independent cause of cardiovascular 
events, such as stroke, cardiomyopathy, coronary artery 
disease (CAD), myocardial infarction, cardiac insuffi-
ciency and sudden cardiac death (30). CVD, including 
heart disease, vascular disease and atherosclerosis, are 
the most critical global health threat, contributing to 
more than one-third of the global morbidity (21). CVD 
is the highest cause of death globally, too (31). In most 
cases, clinical manifestations of CVD result from ath-
erosclerosis, which was identified as a lipid-storage dis-
ease. At the present time, CVD is recognized as a chron-
ic inflammatory condition of the vessel wall, that results 
from the transendothelial passage (transcytosis) of cho-
lesterol-rich atherogenic Apo-B lipoproteins from the 
plasma into the intima (21). It is likely that inflamma-
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Table 2. Age-related alterations contributing to the increased prevalence of the MS 
in elderly subjects
Abbreviations: MS-metabolic syndrome; IR-insulin resistance; ER-
-endoplasmic reticulum
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(5, 21, 24, 30, 31). In particular, obesity as the most com-
mon nutritional disorder in industrialized countries, is 
closely related to impaired endothelial function, a well-
known marker of preatherosclerotic disease (21, 32). 
Having in mind the growing population of overweight 
and obese people worldwide, along with an increasingly 
aging population, understanding the pathophysiology 
of obesity on cardiovascular system is essential. The 
mechanisms linking obesity-related vascular disorders 
and low grade inflammation in aging process are the 
focus of this paper. 
INFLAMMATORY RESPONSE OF THE VESSEL 
WALL IN OBESITY
The term endothelial dysfunction refers to a maladapt-
ed endothelial phenotype characterized by reduced 
nitric oxide (NO) bioavailability, increased oxidative 
stress, elevated expression of proinflammatory and 
prothrombotic factors, and abnormal vasoreactivity to 
endothelial-dependent stressor (32). Experimental and 
clinical data support a link between systemic inflam-
mation and endothelial dysfunction (21, 25, 30, 32, 33). 
Moreover, endothelial dysfunction has increasingly 
been recognized to play an important role in a number 
of conditions associated with a high prevalence of ath-
erosclerotic CVD (21, 25, 30). It is regarded as an early 
stage of atherosclerosis, which is a chronic inflammato-
ry disease (21).
Foam cells
Experimental atherosclerosis induced by high-cho-
lesterol diet is often associated with pulmonary em-
physema (34-37), increased levels of triglycerides (TG) 
and high concentrations of free fatty acids (FFA) in the 
blood and lung tissue (34). In rabbits, after a month of 
hypercholesterolemic diet, aortic lesions become micro-
scopically visible. They are characterized by the accu-
mulation of foam cells in the internal elastic membrane, 
while the endothelial surface is intact. Foam cells are a 
characteristic feature in the tissue response associated 
with bronchial obstruction (34-37).
In an experimental model of atherosclerosis induced by 
a high-cholesterol diet, monocytes are first cell adjacent 
to the endothelium. Then they migrate into the suben-
dothelial space, swallow the oxidized cholesterol, and 
transform it into foam cells (33). Hypercholesterolemia 
associated with elevated levels of atherogenic lipopro-
teins (low density lipoprotein /LDL/ and very low den-
sity lipoprotein /VLDL/) in the blood, leads to chronic 
presence of LDL in the arterial wall (21). This condition 
enhances fatty streaks formation, because lipid migra-
tion into the subendothelium is greater than its remov-
al from the arterial wall. It is known that local cytokine 
secretion and modification of native lipoprotein parti-
cles, that are internalized by vascular macrophages via 
the scavenger receptors class A (SRA) on the surfaces 
of these cells, lead to the formation of foam cells. Thus, 
exacerbation of local inflammatory process in the vas-
cular tissue, due to generation of ROS, resulting in fur-
ther lipoprotein modification and cytokine production 
(33). It has been shown that mononuclear phagocytic 
blood cells take part in the phagocytosis of native parti-
cles to a lesser extent, and of modified LDL particles to 
a greater extent after their binding to the SRA. Howev-
er, these particles may directly migrate into the suben-
dothelium, being subject to phagocytosis, whereas SRA 
play an important role in the process. These receptors, 
which mediate the delivery and degradation of mod-
ified LDL particles, do not operate on the principle of 
negative feedback, so even when a large amount of lipid 
particles is accumulated in the cell, the intake continues, 
which leads to the formation of foam cells (38). In a state 
of continuous inflammation, the concentration of LDL 
particles in blood increases and through the process 
of passive diffusion they penetrate the arterial intima, 
where they are trapped by glycosaminoglycans, where-
as ROS are being affected as well. LDL particles become 
highly sensitive to different stimuli, and may be modi-
fied by oxidation, glycosylation, or by incorporation into 
immune complexes. In addition, LDL particles interact 
with proteoglycans (biglycan and decorin) and form ag-
gregates, with a catalytic activity of sphingomyelinase, 
cathepsin D, cathepsin F and lysosomal acid lipase (39). 
The ability of oxidized LDL molecules (oxLDL) to in-
duce accumulation of cholesterol in macrophages was 
their first described proatherogenic property. Other 
proatherogenic effects of oxLDL particles, referring to 
endothelial cells, include expression of growth factors 
affecting smooth muscle cells, generation of superox-
ide anion (O2), and endothelial cells apoptosis (38). The 
human endothelial receptor that mediates uptake of 
oxLDL belongs to C type lecitin family and is referred 
to as LOX-1 (lecitin-like oxLDL receptor-1) (33). Foam 
cell formation is also induced by receptors involved in 
oxLDL uptake (CD34, macrosialin/ CD68 /) and HDL 
receptor, which is referred to as SB-1 (33).
It is believed that macrophage-colony stimulating factor 
(M-CSF), interleukin-3 (IL-3) and granulocyte mono-
cyte colony stimulating factor (GM-CSF) play a key role 
in the process of foam cell formation (40).
Apart from macrophages, foam cell formation is also 
promoted by vascular smooth muscle cells with proper-
ties of lipophages (41). 
Preatherosclerotic disease 
Numerous animal studies have shown that activation of 
endothelial cells and expression of specific molecules, 
responsible for adhesion, migration and accumulation 
of monocytes and T-lymphocytes, play a crucial role in 
atherosclerosis (33).
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There is evidence that a high cholesterol diet is associ-
ated with fast focal expression of vascular cell adhesion 
molecule-1 (VCAM-1) at predilection sites. In addition, 
lysophosphatidylcholine, a component of modified lipo-
protein, activates VCAM-1 gene transcription in endo-
thelial cells. Lipoprotein(a), however, induces a dose-de-
pendent expression of intercellular adhesion molecule-1 
(ICAM-1) on endothelial cells, but it does not affect the 
expression of VCAM-1 and E-selectin. Furthermore, 
native LDL molecules, binding to the LDL receptors, 
increase the concentrations of VCAM-1 and E-selectin 
in human vascular endothelial cells (41). On the other 
hand, expression of these molecules is induced and en-
hanced by tumor necrosis factor alpha (TNFα) and in-
terleukin-1 beta (IL-1β), which originate either from the 
circulating blood or the vascular wall. These molecules, 
which are part of the existing local or systemic inflam-
matory reaction, apart from stimulating the expression 
of adhesion molecules, lead to changes in procoagulant 
and fibrinolytic endothelial cells, and the surface of the 
endothelium becomes thrombogenic. Modifying the 
properties of endothelial morphology, these cytokines 
affect the production of NO and prostacyclin, inducing 
endothelium to synthesize other cytokines, which en-
hances their proinflammatory activity. IL-1 and TNFα, 
endothelial cell activators, induce synthesis of specific 
membrane glycoproteins, redistributing the cytoskele-
ton of endothelial cells and increasing the synthesis of 
platelet-activating factor (PAF). PAF is a phospholipid 
with potential proinflammatory and thrombogenic 
properties. Its specific significance in atherosclerosis 
is indicated by the fact that components similar to this 
phospholipid are present in oxLDL, and that blockade 
of PAF receptors completely blocks  effects of oxLDL 
molecules on peripheral mononuclear cells, in regard 
to the secretion of interferon-γ (IFN-γ) and partly to 
the secretion of TNFα. IL-1 and TNFα also stimulate 
endothelial cells to produce interleukin-8 (IL-8) that 
strongly attracts and activates leukocytes. Migration 
of leukocytes through the morphologically intact en-
dothelium involves direct migration as a response to 
other cytokines, so-called chemokines. In the early 
phase of atherogenesis these are monocyte chemotactic 
protein-1 (MCP-1), localized in atherosclerotic lesions, 
IL-8, interleukin-16 (IL-16), and C5a-receptor fragment 
peptide, released in hypercholesterolemia (38, 40).
Inflammatory response has been confirmed to affect ac-
cumulation of lipoproteins in the arterial wall. Inflam-
matory mediators (TNFα, IL-1 and M-CSF) increase the 
binding of LDL to the endothelium and smooth muscle 
cells (33). After binding to SRA in vitro, modified LDL 
particles initiate a series of intracellular events, among 
which activation of urokinase and inflammatory cyto-
kines plays an important role. In this way, due to the 
presence of lipids, a vicious cycle of inflammation is 
maintained in the arteries, as well as modification of 
lipoproteins and continuous inflammation (38, 41). 
Thus, LDL molecules enhance the expression of SRA on 
macrophages and in synergy with inflammation facili-
tate formation of foam cells (41). Also, it should be noted 
that a large number of activated macrophages is under-
going apoptosis, after which they release lipid content 
into the matrix and form the lipid nucleus of atheromas 
(40). 
Various studies demonstrate the involvement of im-
mune factors in the etiology of atherosclerosis (21, 25, 
33, 38, 40). Apart from antigens responsible for immune 
responses leading to atherosclerosis, special attention 
is paid to vascular wall antigens. For example, aging 
causes loss of elastin natural properties, and thus it be-
comes susceptible to deposition of calcium and elastoly-
sis. Enhanced decomposition of insoluble elastin in the 
vascular wall leads to the appearance of peptides in the 
blood stream, whereas anti-elastin antibodies are cre-
ated in response to them (40). Rabbits with experimen-
tal atherosclerosis exhibit a progressive titer increase of 
these antibodies, as well as abnormal accumulation of 
microfibrils in the elastic tissue, which is closely asso-
ciated with excessive elastolysis of preformed or newly 
formed elastic fibers during elastic tissue remodeling. 
Enhanced synthesis of microfibrils may occur in re-
sponse to elastolysis as a reparative phenomenon, but 
also represents a response of the blood vessel wall to 
elastolysis (33). In addition, atherosclerotic lesions accu-
mulate ‘’senescent’’ cells defined by markers of replica-
tive senescence (senescence-associated b-galactosidase) 
and telomere shortening. Then, replicative senescence 
induced inflammatory gene expression (1).  
Histochemical methods showed an increased non-spe-
cific esterase activity of macrophages in the arterial walls 
during atherogenesis induced by hypercholesterolemic 
diet. It has also been observed that the amount of ester-
ase is directly proportional to the degree of saturation of 
the intima with lipoproteins and other macromolecules 
(33). Besides, it has been established that different local 
stimuli (immune complexes, antigens, lymphokines, 
bacterial components, etc.) may trigger the release of hy-
drolytic lysosomal enzymes into the extracellular space 
with autodestructive consequences. In addition, the de-
gree of esterase activity in mononuclear cells correlates 
with cell viability and mitotic capacity (42).
In the vessels of obese patients, a shift of the normal 
prevalence of NO-mediated  vasodilator tone towards 
an enhanced endothelin-1 (ET-1) –mediated vasocon-
striction has, in fact, been observed (32). The presence of 
endothelial dysfunction in patients with obesity and in-
sulin resistance (IR) was first reported by Steinberg et al, 
over a decade ago. These authors demonstrated a blunted 
increase of leg blood flow in response to graded intraar-
terial doses of the muscarinic receptor agonist metha-
choline in patients with elevated BMI or type 2 diabetes 
compared to lean controls (43). These observations have 
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been followed by exploration of the cellular and molec-
ular action of insulin on the vasculature. Quon and col-
leagues 2007 demonstrated that the molecular signaling 
pathways mediating insulin stimulation of NO produc-
tion in endothelial cells are similar to signaling path-
ways mediating insulin activation of glucose transport 
in classical target tissues (i.e. the phosphatidylinositol 
3-kinase /PI3K/ pathway) (44). Also, it has been shown 
mild elevation of fasting blood glucose after age 40 (1). 
The progressive glycemia of normal aging is emerging 
as a canonical feature of aging paralleling the increase 
in systolic blood pressure and atherosclerosis. It seems 
potentially important that mortality risk at later ages be-
comes increasingly sensitive to blood glucose (45).
ADIPOSE TISSUE AS AN ENDOCRINE ORGAN
For many years, adipose tissue was regarded merely as 
a heat insulator and a store of excess FFA that could be 
released when needed (46). During recent years, in fact, 
adipose tissue has been acknowledged as a major endo-
crine and paracrine organ, that produces adipokines, 
hormones and cytokines (32, 46, 47). These molecules 
contribute to the modulation of insulin activity and re-
sistance, and metabolism of fat and glucose indirectly 
determining atheroslerosis (32). 
Adipose tissue contains various cells, such as adipo-
cytes, preadipocytes, vascular cells, endotheliocytes, 
lymphocytes and macrophages expressing CD14 re-
ceptors (47). In obesity, the increased production of in-
flammation mediators in the adipose tissue, liver, pan-
creas and skeletal muscles causes subclinical metabolic 
inflammation (32, 47). This inflammation affects the 
metabolic and secretory function of adipose tissue and 
plays a leading role in the development of obesity ac-
companying MS, diabetes mellitus and atheroslesrosis 
(32, 46, 47). The main source of proinflammatory me-
diators in this process are CD14+ cells. Furthermore, 
metabolic inflammation also involved cell infiltration, 
fibrosis development, impaired microcirculation, en-
hanced adipokines and proinflammatory cytokines in 
the visceral adipose tissue and increase of non-specific 
inflammatory biomarkers (CRP, fibrinogen, etc.) and 
leukocytes in the blood (47).
Perivascular adipose tissue (PVAT) surrounds blood 
vessels in changing amounts and is produced from the 
vascular lamina adventitia in response to circulating 
factors and local stimuli (46). It can be considered as a 
paracrine organ that transduces metabolic signals from 
the adipose tissue to blood vessels (48). Thus, PVAT 
can play an active role in regulating vascular tone and 
releases adipocyte-derived vascular relaxation factors 
into blood vessels (46, 48). Excess calories and inactivity 
enlarge PVAT depots with potentially unfavorable con-
sequences and an increase in PVAT is suggested to me-
diate morphologic changes associated with an increse in 
vascular stiffness seen in obesity (46). In obesity, PVAT 
dysfunction triggers inflammation, oxidative stress, 
and hypoxic processes to promote vascular dysfunction 
(32). 
PVAT secretes yet unidentified perivascular adipose 
tissue derived relaxing factor (PVADRF). In obesity, 
dysfunction and inflammation of adipose tissue result 
in impaired production of PVADRF (48). It has been 
shown a critical role of ROS from PVAT in the impair-
ment of endothelium-dependent vasodilation in diet-in-
duced obese mice (32, 48). Many adipokines with an-
ticontractile properties, including leptin, adiponectin, 
angiotensin 1-7, hydrogen sulfide, visfatin and methyl 
palmitate have been proposed as potential candidates 
for PVADRF. However, none of them fully mimics the 
vascular effects of PVADRF and its precise identity re-
mains to be elucidated (48).
Considering that PVAT contributes to vascular diseas-
es, it is suggested that PVAT may be a novel target for 
treatment of atherosclerosis and restenosis after coronary 
intervention (48). Restenosis at sites of vascular injury 
following angioplasty is a phenomenon in which vascu-
lar smooth muscle cell (VSMC) phenotype switches to 
proliferation and migration as in the case in atheroscle-
rosis (48). The local microenvironment, influenced by 
growth factors and inhibitors, is very important for the 
phenotypic conversion (32, 48). There is ample evidence 
that factors released from PVAT regulate VSMC prolifer-
ation and migration (32, 46, 48).  It is also suggested that 
epicardial adipose tissue may serve as a local source of 
proinflammatory cytokines involved in the development 
of CAD. It was found in patients that there is an indepen-
dent relationship between increased epicardial adipose 
tissue and carotid intima-media thickness (IMT) (48).
Adipokines and inflammation
The adipocytes, preadipocytes and macrophages within 
adipose tissue secrete a variety of hormones known as 
adipokines (46, 49). The list of adipokines continues to 
grow to hundreds of factors (32, 48). Some of these ad-
ipokines like leptin play a role in homeostasis of body 
weight by controlling food intake (48). High leptin 
concentrations correlate with adverse cardiovascular 
outcomes in obese patients (32). Hyperleptinemia has 
been shown to be an independent risk factor for CAD 
and a strong predictor of acute myocardial infarction 
and stroke (32, 50). Besides, adipose tissues expresses 
enzymes involved in the angiotensin system (RAS) (re-
nin, angiotensin-converting enzyme /ACE/), as well as 
the nonrenin-angiotensin system (NRAS) (cathepsin D, 
cathepsin G, tonin, chymase) (21). 
More recently, it has become clear that many adipokines 
are mediators in the “adipo-cardiovascular axis”, the cross 
talk between adipose tissues, the heart and the vasculature 
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(46, 48, 49). Related to CVD one can distinct “healthy” (of 
which adiponectin and omentin are best characterized) 
and “unhealthy” adipokines. Interestingly, the “healthy” 
adipokines are decreased in obesity while the “unhealthy” 
adipokines, such as TNFa, IL-6, plasminogen activator 
inhibitor-1 (PAI-1), adipocyte fatty acid binding protein 
(A-FABP), lipocalin 2, chemerin, leptin, visfatin, vaspin, 
resistin are upregulated in obesity-related vascular disor-
ders (48). The most important adipokines and their effects 
on vascular function is shown in Table 3. It is now evident 
that many of these adipokines have the ability to influ-
ence other tissues, such as liver and muscle (46). These 
molecules secrete into the circulation and participate in 
regulation of a number of chronic diseases affecting in-
sulin sensitivity, glucose and lipid metabolism, as well as 
cardiovascular homeostasis (49).
Under normal conditions, the adipocyte is a site of lipid 
synthesis, uptake and storage (46). Secreted adipokines 
function as either endocrine, paracrine or autocrine me-
diators (32, 46, 49). Increases of adipocyte size can lead 
to deleterious alterations in insulin sensitivity caused by 
a decrease in adiponectin secretion, an increase in the re-
lease of FFA and the induction of inflammatory media-
tors (46, 49). Large adipocytes are more insulin-resistant 
and lipolytic, and release more inflammatory cytokines 
and less adiponectin. They are also more frequently fo-
und in individuals with obesity-related metabolic disor-
ders (46). Enlargement of adipocytes is also associated 
with physical stress and increased ROS production (1, 
46). These stress factors induce production of inflam-
matory adipokines, such as IL-6 and serum amyloid A 
(SAA), that are released into the circulation and mediate 
the recruitment of activated monocytes into adipose tis-
sue (46, 49). In obesity, under these conditions, adipose 
tissues, especially activated macrophages, produce pro-
inflammatory adipokines, such as TNFa, leptin, IL-6, 
monocyte chemoattractant protein-1 (MCP-1), lipoca-
lin-2, resistin, A-FABP, PAI-1, that further encourage va-
scular disease (21, 46, 49). In these circumstances, pro-
duction of adiponectin is markedly reduced (46-59) and 
inversely correlated with BMI and visceral fat (32). All of 
these changes have been shown to be key contributors to 
obesity-related vascular disease (46, 49). 
Adipokine Effects on vascular function
Adipocyte fatty acid binding protein (A-FABP) proinflammatory effect
Adiponectin direct vasodilatory effect; ↑ VSMC proliferation and migration; ↑ vascular permeabili-
ty; ↑ oxidative stress; insulin-sensitizing effect; anti-inflammatory  and
anti-dyslipidemic activities 
Angiotensinogen vasoconstrictor; proinflammatory effect; 
↓ NO bioavailability
Apelin proinflammatory effect
Atrial natriuretic peptide (ANP) blood volume control
Chemerin proinflammatory effect
C reactive protein (CRP) proinflammatory effect; strong independent risk factor for endothelial dysfunction
Endothelin-1 (ET-1) vasoconstriction; VSMC proliferation; cell adhesion
Free fatty acids (FFA) ↓ endothelium-dependent vasodilation
Ghrelin vasodilation; ↑ NO production
Interleukin-1b (IL-1b) proinflammatory effect
Interleukin-6 (IL-6) proinflammatory effect; strong independent predictor for future cardiovascular events
Interleukin-8 (IL-8) proinflammatory effect
Leptin direct vasodilatory effect; ↑ VSMC proliferation and migration; ↑ vascular permeabil-
ity;  ↑ oxidative stress
Lipocalin-2  proinflammatory effect
Monocyte chemoattractant protein-1 (MCP-1) proinflammatory effect
Nitric oxide (NO) Vasodilation
Omentin vasoprotective effect
Perivascular adipose tissue derived relaxing fac-
tor (PVADRF)
anticontractile vascular properties
Plasminogen activator inhibitor-1 (PAI-1) ↑ VSMC proliferation
Reactive oxygen species (ROS) eNOS uncoupling; proinflammatory effect
Resistin reduced eNOS expression; ↑ endothelial cell activity;
↑ VSMC proliferation;  ↑VSMC migration 
Retinol-binding protein 4 (RBP4) proinflammatory effect
Serum amyliod A (SAA) proinflammatory effect
Tumor necrosis factor a (TNFa) ↓ endothelium-dependent vasodilation;




Table 3. Effects of adipokines on vascular function
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As in obesity, also aging is associated with altered func-
tion, size and number of adipose cells, with altered dis-
tribution of adipose tissues in the body and with hypoxia 
in adipose tissue, especially in the visceral depots (48).
Oxidative stress and inflammation
Endothelial dysfunction in obesity is characterised by 
increased generation of ROS (32, 50). This is contribut-
ed by vascular cells and inflamed hypertrophied adipo-
cytes as a result of endoplasmic reticulum (ER) stress 
and mitochondrial dysfunction (8, 21, 50). Enzymes 
of mitochondrial electron transport chain, xanthine 
oxidase, cyclooxygenases, lipoxygenases, myeloperoxi-
dases, cytochrome P450 monooxygenase, heme oxygen-
ases, peroxidases and NAD(P)H oxidases contribute to 
endothelial dysfunction (50). Uncoupling of endothelial 
nitric oxide synthase (eNOS) is a major contributor to 
ROS production (32, 50). This results in decreased NO 
bioavailability, increased superoxide anion (O2
.) pro-
duction and formation of peroxynitrite (ONOO-), a key 
mediator of lipid peroxidation and foam cell formation 
in atherosclerotic lesions (50). Additionally, ROS ac-
cumulation results in activation of signalling cascades 
that regulate transcription factors, including nuclear 
factor kappa beta (NF-kb) adhesion molecules, che-
motactic factors, antioxidant enzymes, and vasoactive 
substances promoting adhesion and migration of circu-
lating monocytes initiating atherosclerotic lesions (39, 
50). Dysregulated adipokine production leading to in-
creased ROS generation forms a major feedback loop in 
initiation, maintenance and progression of endothelial 
dysfunction (50). 
Insulin resistance and inflammation
Inflammation and IR in obese individuals are mutually 
amplifying processes that increase the risk of cardiovas-
cular morbidity and mortality (32). The accumulated 
evidence indicates that IR is a key pathogenic factor for 
MS (59). Namely, it is generally believed that elevated 
blood pressure, dyslipidemia and impaired glucose tol-
erance are caused by IR (24, 25, 27, 59). 
IR is often associated with increased adipose tissue 
mass (59). Proinflammatory cytokines produced by ad-
ipocytes contribute, at least in part, to IR by interfer-
ing with normal insulin receptor intracellular signaling 
(32). On the other hand, obesity-related IR is well-known 
to promote inflammation through diverse mechanisms 
including oxidative stress, stimulation of proinflamma-
tory adipokines, AGEs, and FFAs (32). Dysfunctional 
adipose tissue with low grade, chronic and systemic in-
flammation links the metabolic and vascular pathogen-
esis including dyslipidemia, low grade inflammation 
and IR and is a hallmark of disorders such as type 2 dia-
betes and CVD (46). However, lifestyle factors and, to a 
lesser degree, genetic factors, are also involved (32, 46).
Scheme 1. Inflammation and obesity-related vascular disorders 
Abbreviations: CRP- C reactive protein; DM - diabetes mellitus; IGF-1 - insulin like growth factor-1; IL-6 - interleukin-6; FFA-free fatty 
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Lipid accumulation in liver and muscle is an early hall-
mark of type 2 diabetes (11, 12, 46). In the pancreas, lip-
id accumulation has been shown to precede suppressed 
glucose-mediated insulin production (46). In the lip-
id-overloaded heart, metabolic dysregulation may in-
duce IR resulting in impaired glucose oxidation, and, 
ultimately, heart failure (6, 46).
Large adipocytes are more frequently found in subjects 
with impaired glucose tolerance and type 2 diabetes 
than those with a similar degree of adiposity but with 
normal glucose tolerance, and impaired adipocyte dif-
ferentiation appears to be one of the most important 
factors in the progression of type 2 diabetes (46). Insu-
lin has several functions, including the transport of nu-
trients into cells, the regulation of gene expression and 
energy homeostasis. It acts on a number of target tissues 
and through many different intracellular signaling cas-
cades (8, 10, 14). Elevated levels of intracellular FFAs can 
blunt the response to insulin and subsequent metabolic 
effects (32, 46).
Insulin receptor substrate-1 (IRS-1) is a key molecule 
in the insulin signaling pathway and failure to activate 
IRS-1 leads to systemic IR (46). Inhibitory phosphory-
lation of IRS-1 can be induced through inflammatory 
agents, such as TNFa and IL-6, but also through activa-
tion of receptors, such as the Toll-like receptors (TLR), 
or intracellular molecules such as lipids and ROS (27, 
46). Activation of the TNFa and IL-6 receptors induces 
activation of important activators of inflammation i.e. 
IkB kinase (IKKb) and Janus kinase (JNK) (46). JNK is 
also activated by FFAs and ER stress, factors that are as-
sociated with obesity-induced activity (25, 27, 46). IKKb 
does not phosphorylate IRS-1, but causes IR through 
activation of NFkB (25). Supressor of cytokine signal-
ling (SOCS) inhibits insulin actions on IRS-1, either by 
interfering with the tyrosine phosphorylation, or by tar-
geting IRS-1 for proteosomal degradation (46).
The consequences of decreased insulin production as 
a result of ectopic lipid accumulation in the pancreas 
combined with a diminished activation of the insulin 
receptor in adipocytes results in an impairment of in-
sulin-stimulated glucose transport, a reduced anti-lip-
olytic effect, an increase in the amount of FFA released, 
impaired preadipocyte differentiation and a decrease in 
lipoprotein lipase (LPL) production and activity (46). 
These effects will lead to the development of IR, type 2 
diabetes and CVD (46, 51). 
An increase in the amount of AGEs also contribute to 
the development of vascular complications in diabe-
tes, inducing endothelial dysfunction (16, 17, 51). Sev-
eral mechanisms by which this heterogeneous group 
of compounds formed by nonenzymatic glycation of 
proteins and lipids lead to endothelial dysfunction have 
been proposed, such as the accumulation of AGEs in the 
extracellular matrix, the binding of circulating AGEs to 
the endothelial surface receptor for AGEs (RAGE) with 
subsequent generation of ROS, the cytokine release and 
the expression of cell adhesion molecules (51).
NAFLD AND ADIPOSE TISSUE INFLAMMATION
The liver is an organ that is vulnerable to ectopic fat 
accumulation (60). Currently, the incidence of  nonal-
coholic fatty liver disease (NAFLD) mirrors the preva-
lence of obesity and MS, and NAFLD is now one of the 
most common causes of chronic liver disease worldwide 
(61). Notably, NAFLD is not a single disease entity, but 
describes a spectrum of liver conditions. The disorder 
ranges from simple fatty liver (steatosis) to more severe 
steatosis coupled with marked inflammation termed 
nonalcoholic statohepatitis (NASH), which can progres 
to fibrosis, and subsequently to liver cirrhosis, liver fail-
ure and hepatocellular carcinoma (62).
NAFLD is now considered as a hepatic manifestation of 
MS (60-62). In support of this, recent studies have shown 
that severe NAFLD is linked to an incressed risk of 
CVD (25, 27, 60, 62). These studies suggest that NAFLD 
may be actively involved in the pathogenesis of CVD, 
potentially through the increased release of proathero-
genic factors from the liver (CRP, fibrinogen, PAI-1 and 
other inflammatory cytokines). Alternatively, NAFLD 
is involved in in whole-body IR and dyslipidemia. For 
example, once significant hepatic steatosis occurs, the 
liver becomes insulin resistant and overproduces both 
glucose and VLDL, which in turn leads to hypergly-
cemia, hypertriglyceridemia and low concentration of 
high density lipoproteins (HDL) (62). However, whether 
IR precedes ectopic fat deposition or whether fat accu-
mulation is a consequence of IR remains an unanswered 
question (64).
As previously described, ectopic fat is an important 
source of inflammatory mediators, cytokines and adi-
pokines. It is possible that adipose tissue inflammation 
plays a role in the pathogenesis of NAFLD (63). Indeed, 
analysis of adipose tissue from subjects with severe liv-
er steatosis has suggested that inflamed adipose tissue 
characterises people with a high liver fat content (65). 
In mice, the overexpression of an inflammatory mark-
er in adipose tissue, macrophage chemotactic protein-1 
(MCP-1), is thought to lead to macrophage infiltration 
and hepatic steatosis (66). However, it is also possible 
that hepatic inflammation may precede that of oth-
er insulin-sensitive tissues, as the hepatic activation of 
NFkB via overexpression of IKKb can induce IR in the 
liver and muscle in addition to an increase in signs of 
systemic inflammation (IL-6) (63). In response to these 
findings, one can draw similarities between hepatic fat 
and more traditional sites of proinflammatory adiposo-
pathic ectopic fat, predominantly influenced by a high 
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fat diet (67). Therefore, liver with NAFLD may play an 
even larger role in the whole body inflammatory state, 
because the liver itself is in an advanced state of inflam-
mation (68, 69).  
INFLAMMATION, OBESITY-RELATED 
VASCULAR DYSFUNCTIONS AND AGING 
PROCESS
Cardiovascular events, diabetes mellitus resulting from 
the MS as well as cancer are the common cause od death 
of aging humans (27, 28). Why is it so? As it is previously 
described, advancing age affects all levels of patgogenic 
components of the MS (27-29). With aging we assist to 
a change in the body composition characterised by the 
redistribution of the body composition in favour of the 
adipose tissue. The increase in the adipose tissue is es-
pecially marked centrally, as well as in muscle and liver. 
In the mean time the lean body mass is also decreasing, 
which favours the IR in the muscle (27). In addition, the 
aging process is associated with a low grade inflamma-
tion due to the deregulated functioning of the innate 
immune system over adaptive immune system resulting 
from chronic antigenic stimulation of all types includ-
ing infections and nutrition (1, 27, 70, 71). This results in 
the increase in circulating levels of FFA and proinflam-
matory cytokines enforcing the already existing IR (27). 
Thus, the better understanding of the interplay between 
the metabolic response and immunosenescence could 
lead to important understanding of both processed 
during aging.  
Aging is also associated with a change in the hormones 
implicated in metabolism including insulin like growth 
factor-1 (IGF-1), the growth hormone and insulin (1, 27, 
72-74). IGF-1 recently has become a major determinant 
in nematode and fly longevity (27). Evidence suggests 
that disruption in IGF-1 signalling uniformly extends 
lifespan in animal species (1, 27). Of course, no direct 
conclusion can be drawn for human longevity (27). 
However, the decrease, as well as the increase IGF-1 
levels were related to various diseases (27, 74). Insulin 
sensitivity declines with age and is associated with in-
creased morbidity and mortality due to atherosclerosis, 
CVD, obesity and diabetes, all related to dysregulation 
of the aging immune system (immunosenescence) (27, 
31, 77), as well as to dementia (20). Studies in healthy 
centenarians show enhanced insulin sensitivity demon-
strating an important role of healthy insulin signalling 
for long life (27). How exactly it could happen is still 
to be discovered. Probably the newly discovered SIRT 
gene family, actually seven members could play an im-
portant role (1, 27). Nevertheless, vigorous prevention 
and/or treatment of IR and components of the MS could 
have important implications for human longevity (27).  
Caloric restriction and inflammation
Many observational and experimental studies have con-
sidered that caloric restriction may be associated with 
life prolongation, possibly through an improvement of 
the cell redox balance (78). Also, increase degeneration 
of mitochondrial ROS and oxidative damage seem to 
be differently induced by nutritional perturbation and 
state (31, 78, 79). In animal experiments, hypocaloric 
diet and antioxidant supplementation were associated 
with improvement of some tissue functions and redox 
states that, conversely, were oxidatively depressed in 
aged control animals (78). A key event associated with 
diet restriction is the activation of a class of genes be-
longing to the SIRT family, which is involved in cell 
maturation and apoptotic processes (1, 27, 78). Recently, 
it is shown that resveratrol, an antioxidant poliphenol of 
red wine, was able to activate these genes by mimicking 
the effect of diet restriction (31, 78). Successively, it is re-
ported that high dose of resveratrol was able to contrast 
the development of CVD and diabetes in mice fed with 
hypercaloric diet, suggesting a role for oxidative stress 
in systemic inflammation and damages in conditions 
stimulating the MS (31, 78). 
Diet has major systemic influences on inflammation 
through the levels of energy intake, energy storage in 
fat depots, and ingested AGEs produced during cook-
ing (1). As a general principle, innate immune responses 
are regulated by the energy available (1, 3, 70). Caloric 
restriction, besides limiting the febrile response, atten-
uates other acute phase responses (1). A systemic mech-
anism in caloric restriction may be elevation of corti-
costeroids, which is a broad gluconeogenic homeostatic 
response to partial starvation to maintain sufficient lev-
els of blood glucose (1, 2). Lowering of blood glucose by 
caloric restriction attenuated production of AGEs, that 
further kindling inflammatory process (1). Besides, 
AGEs can act directly on pancreatic cells to impair in-
sulin secretion through induction of iNOS (1). The ox-
idative load also is diminished by caloric restriction in 
most tissues (1, 27, 31, 67, 78, 80-82).
Gene expression profiling studies consistently show that 
caloric restriction attenuates the increased expression 
of cytokine and complement factor genes during aging 
in brain, heart, and liver (1, 83, 84). Caloric restriction 
also attenuates atherosclerosis, cancer and Alzheimer’ 
disease in rodent models (1, 27, 78). In moderately obese 
patients, diet restriction lowered blood CRP and IL-6, 
with correspondingly lower incidence of cardiovascular 
events (1). 
CONCLUSION
The pathogenesis of obesity-related vascular disorders 
has not been fully elucidated. The fundamental role of 
inflammation in aging process is now widely recognized, 
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particularly for atherosclerotic disease which begins 
before birth. The strong age trends for elevated blood 
glucose and glycated proteins during starting midlife 
is hypothesized to be a fundamental driver of vascular 
disease and the acceleration of risk for cerebrovascu-
lar events. Obesity and MS are important risk factors 
for metabolic and CVD. Despite a well-known genetic 
component, this risk appears to originate from several 
abnormalities in adipose tissue function associated with 
a chronic inflammatory state. These conditions disrupt 
vascular homeostasis by causing an imbalance between 
the NO pathway and the ET-1 system, with impaired in-
sulin-stimulated endothelium-dependent vasodilation. 
Many research efforts are still required to unravel the 
complex relation between adipose tissue and CVD and 
the potential role of adipokines as biomarkers. A hope 
remains that future research on the role of these biologi-
cal active molecules in the pathogenesis of obesity-relat-
ed vascular disfunctions will shed light on yet unknown 
potential therapeutic modalities. 
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